Global Cardiac Valve Market Size, Share, Forecast Report, 2020-2027

Cardiac valve or heart valve allows blood to flow in only one direction through the heart; human heart is made of four valves. A cardiac valve opens or closes compulsory on differential blood pressure on each side.

The market is driven by increasing number of people with cardiovascular diseases and increasing number of cardiac surgery. Additionally, increasing prevalence of diabetes and obesity, adoption of deskbound lifestyle, rising geriatric population, and excessive use of tobacco and alcohol boost the market growth.

On the other hand, higher cost of treatment methods may hamper the growth of the Europe and the Middle East & Africa cardiac valve market.

The EMEA cardiac valve market is expected to grow at a CAGR of 6.5% during the forecasted period.
Segmentation
The EMEA cardiac valve market is segmented on the basis of types, by diseases, by treatment, and by end users.

On the basis of types the market is segmented into trans-catheter heart valve, tissue heart valve, and mechanical heart valve, others.

On the basis of disease, the market is segmented into aortic valve replacement, heart valve disease, mitral valve stenosis, and others.

On the basis of treatments, it is segmented into valve replacement, valve repair, and others.

On the basis of end users, the markets segmented into cardiac research institute, hospital & clinics, and others.
Key players
Medtronic, Edwards Lifesciences Corporation (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical, Inc. (an Abbott Laboratories Company) (U.S.), LivaNova PLC (U.K.), Symetis SA (Switzerland), Jenavalve Technology, Inc. (Germany), CryoLife, Inc. (U.S.), TTK HealthCare (India), Colibri Heart Valve, LLC (U.S.), Lepu Medical Technology Co., Ltd. (China), and Braile Biomédica (Brazil)